Basis for drug selectivity of plasmepsin IX and X inhibition for Plasmodium falciparum and vivax
Anthony N. Hodder(The University of Melbourne), Alan F. Cowman(Walter and Eliza Hall Institute of Medical Research), John A. McCauley(Fox Chase Cancer Center), Melanie H. Dietrich(The University of Melbourne), Nicholas Murgolo(Merck & Co., Inc., Rahway, NJ, USA (United States)), Brodie L. Bailey(The University of Melbourne), Wai‐Hong Tham(The University of Melbourne), Anna Ngo(Walter and Eliza Hall Institute of Medical Research), Richard W. Birkinshaw(The University of Melbourne), Peter E. Czabotar(The University of Melbourne), Brad E. Sleebs(The University of Melbourne), Tony Triglia(Walter and Eliza Hall Institute of Medical Research), Kym N. Lowes(The University of Melbourne), S.W. Scally(Walter and Eliza Hall Institute of Medical Research), Paola Favuzza(The University of Melbourne), David B. Olsen, Zhuyan Guo(United States Military Academy), Manuel de Lera Ruiz(United States Military Academy)
Cited by 1
Related Papers
Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018
|Cell Death and Differentiation|2018|6.6k
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
|Science Translational Medicine|2015|541
Antibiotic Susceptibility Profiles of <i>Escherichia coli</i> Strains Lacking Multidrug Efflux Pump Genes
|Antimicrobial Agents and Chemotherapy|2001|502
Mechanism and inhibition of the papain‐like protease, PLpro, of SARS‐CoV‐2
|The EMBO Journal|2020|499